Ultrastructural changes in rat locus coeruleus induced by chronic opioids.
The locus coeruleus (LC) is a major noradrenergic nucleus in the brain. The activity of the LC neurons is chronically regulated by opioids. So far, very little is known about the morphological changes induced by chronic treatment with opioids. In the present study, the effects of chronic treatment with morphine and dihydroetorphine, a new narcotic analgesic with lower physical dependence potential than morphine, were investigated on the ultrastructure of the rat LC. Rats received saline or increasing doses of morphine or dihydroetorphine for 5 days by twice daily subcutaneous injections. Withdrawal was precipitated in half of the opioid-treated rats by a single intraperitoneal injection of naloxone 4 h after the last injections of opioids. The ultrastructure of the LC was examined by electron microscopy. Results showed that chronic morphine treatment induced a marked injury to the LC neurons. The primary changes in the cell body were the indentation of nuclei, the fragmentation and degranulation of rough endoplasmic reticulum, as well as the disaggregation of polyribosomes. Myelinoid bodies were seen in the processes. An accumulation of presynaptic vesicles was observed in some of the terminals which formed synaptic junctions with the LC neurons as compared to the normal controls. Naloxone-precipitated withdrawal from morphine did not stop the morphine-induced injury on the LC neurons except that less accumulation of presynaptic vesicles occurred. Chronic dihydroetorphine treatment only induced a slight change in the ultrastructure of the LC neurons. These results indicate that the LC neurons are more vulnerable to chronic treatment with morphine than to that with dihydroetorphine.
Miao
H
H
Institute of Pharmacology and Toxicology, Academy of Military Medical Science, Beijing, China.
Qin
B Y
BY
Yang
Y
Y
Chen
D H
DH
D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D018870:Endoplasmic Reticulum, Rough / Q000187:drug effects / Q000648:ultrastructure; D005048:Etorphine / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D008125:Locus Coeruleus / Q000187:drug effects* / Q000648:ultrastructure*; D008297:Male; D009020:Morphine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D009186:Myelin Sheath / Q000187:drug effects / Q000648:ultrastructure; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009294:Narcotics / Q000494:pharmacology*; D009474:Neurons / Q000187:drug effects / Q000648:ultrastructure; D011132:Polyribosomes / Q000187:drug effects / Q000648:ultrastructure; D051381:Rats; D017208:Rats, Wistar; D013572:Synaptic Vesicles / Q000187:drug effects / Q000648:ultrastructure
D000700:Analgesics; D009292:Narcotic Antagonists; D009294:Narcotics; D009270:Naloxone; D005048:Etorphine; D009020:Morphine; C034765:18,19-dihydroetorphine